Pegaspargase biosimilar - Gennova Biopharmaceuticals

Drug Profile

Pegaspargase biosimilar - Gennova Biopharmaceuticals

Alternative Names: Hamsyl

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gennova Biopharmaceuticals
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia

Most Recent Events

  • 01 Feb 2016 Preclinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, In children) in India (IM) before February 2016 (CTRI/2016/02/006589)
  • 01 Feb 2016 Gennova Biopharmaceuticals plans a clinical trial for Acute lymphoblastic leukaemia (In children) in India (CTRI/2016/02/006589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top